Table 1.
Sample characteristics | No. | Weighted %† |
---|---|---|
Total | 1220 | 100.0 |
Physician characteristics | ||
Age, y | ||
<40 | 262 | 22.0 |
40–49 | 371 | 30.9 |
50–59 | 289 | 23.5 |
≥60 | 298 | 23.6 |
Years since medical school graduation | ||
7–14 | 293 | 25.0 |
15–24 | 372 | 30.9 |
25–34 | 272 | 21.9 |
35–51 | 283 | 22.2 |
Sex | ||
Male | 877 | 65.9 |
Female | 343 | 34.1 |
Race/ethnicity | ||
White, non-Hispanic | 762 | 62.0 |
Other | 458 | 38.0 |
Types of tumors treated | ||
Hematologic cancers only | 140 | 11.7 |
Hematologic and solid | 792 | 64.4 |
Solid tumors only | 284 | 23.9 |
Percentage of time providing patient care | ||
5–75% | 368 | 31.0 |
>76% | 852 | 69.0 |
Affiliation with medical school or hospital | 759 | 62.7 |
Formal training in genomic testing | 680 | 56.2 |
Use of next-generation sequencing gene panel tests | 913 | 74.5 |
Practice characteristics | ||
Practice type | ||
Solo | 52 | 4.3 |
Single specialty | 519 | 42.0 |
Multispecialty | 540 | 44.8 |
Other | 103 | 8.9 |
Located in metropolitan statistical area | ||
Small/Medium | 179 | 14.1 |
Large | 165 | 12.2 |
Very large | 876 | 73.7 |
US geographic region | ||
Northeast | 302 | 26.5 |
Midwest | 286 | 20.9 |
South | 419 | 34.8 |
West | 213 | 17.8 |
Patient volume per month | ||
1–99 | 626 | 52.1 |
≥100 | 594 | 47.9 |
Primary practice provides internal policies or protocols for genomic tests | 579 | 47.9 |
Primary practice has electronic medical record alerts for genomic tests | 199 | 16.6 |
Primary practice provides genomic and/or molecular tumor board for genomic tests | 439 | 36.2 |
Proportion of patients insured by Medicaid≥10% or self-pay or uninsured ≥10% | 910 | 73.8 |
Area-level characteristics | ||
Mean per capita income | ||
>$60 000 | 311 | 26.8 |
$45 000–60 000 | 524 | 42.6 |
≤$45 000 | 385 | 30.6 |
% persons ≥25 years with ≥4 years of college | ||
>45 | 247 | 20.8 |
30–45 | 584 | 48.3 |
≤30 | 389 | 30.9 |
Median gross rent | ||
>$1000 | 467 | 40.8 |
$850–1000 | 397 | 32.0 |
≤$850 | 356 | 27.3 |
Data from the 2017 National Survey of Precision Medicine in Cancer Treatment. Exact wording of survey questions and response options is listed in Supplementary Table 1 (available online).
Percentages weighted to account for complex survey design and survey nonresponse.